ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

NavnABBVON

RangNo.3143

Markedscap$0.00

Fuldt udvandet markedsværdi$0.00

Markedsandel%

Handelsvolumen/markedsværdi (24H)412,835.30%

Cirkulationsforsyning210.07193405

Max Udbud0

Samlet Udbud210.07193405

Cirkulationshastighed%

Udstedelsesdato--

Den pris, som aktivet først blev udstedt til--

Alle tiders høj235.09684688380833,2026-02-17

Laveste pris207.47261007076094,2026-02-04

Offentlig blockchainETH

IndledningAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Sektor

Social Media

• Officiel hjemmeside
• Bloker Explorer

etfindex:mc_etfindex_sourceAnsvarsfraskrivelse: Data leveret af cmc og bør ikke betragtes som investeringsrådgivning.